Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Canadian Rx Imports Would Be 10% Of U.S. Market, Caremark CEO Says

Executive Summary

Prescription drugs from Canada would make up 10% of the U.S. drug market if importation were legalized, Caremark CEO Mac Crawford said Oct. 25

You may also be interested in...



Reimportation Can Be Stopped, Sen. Santorum Says

President Bush is not articulating opposition to price controls when discussing pharmaceutical importation on the campaign trail due to the difficulty of conveying that message to voters, Sen. Rick Santorum (R-Penn.) said in an Oct. 28 interview with "The Pink Sheet.

CVS Endorses Imports; Infrastructure Already In Place, CEO Says

Much of the infrastructure for importing drugs is already in place, CVS CEO Thomas Ryan said May 5 at a meeting of the HHS importation task force

Rx Importation Unsustainable Because Of Supply/Demand Imbalance – HDMA

Increased demand for a small amount of Canadian pharmaceuticals would make a legalized importation system unsustainable, drug distributors told the HHS importation task force

Latest Headlines
See All
UsernamePublicRestriction

Register

PS044889

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel